Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen Smith

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Transplantation and Cellular Therapy|August 9, 2024
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell TransplantationShukaib Arslan, Amrita Desai, Dongyun Yang, et al.
Bone Marrow Transplantation|December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual diseaseAmanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
The Lancet. Haematology|May 18, 2026
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trialAnthony Stein, Yan Wang, Monzr M Al Malki, et al.
Transplantation and Cellular Therapy|May 14, 2023
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisJanny M Yao, Salman Otoukesh, Hanna Kim, et al.
Transplantation and Cellular Therapy|July 5, 2025
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal ImpairmentTina Nguyen, Tanya Markary, Ni-Chun Tsai, et al.
Blood Advances|October 12, 2021
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphomaAlex F Herrera, Joycelynne Palmer, Vikram Adhikarla, et al.
American Journal of Hematology|March 7, 2023
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusionsIbrahim Aldoss, Michelle Afkhami, Dongyun Yang, et al.
Frontiers in Immunology|March 7, 2025
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxisDiana T Samuels, Janny M Yao, Yazeed Samara, et al.
Transplantation and Cellular Therapy|March 30, 2026
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell TransplantationJorge M Ramos Perez, Haoyue Shan, Dongyun Yang, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Transplantation and Cellular Therapy|August 9, 2024
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell TransplantationShukaib Arslan, Amrita Desai, Dongyun Yang, et al.
Bone Marrow Transplantation|December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual diseaseAmanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
The Lancet. Haematology|May 18, 2026
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trialAnthony Stein, Yan Wang, Monzr M Al Malki, et al.
Transplantation and Cellular Therapy|May 14, 2023
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisJanny M Yao, Salman Otoukesh, Hanna Kim, et al.
Transplantation and Cellular Therapy|July 5, 2025
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal ImpairmentTina Nguyen, Tanya Markary, Ni-Chun Tsai, et al.
Blood Advances|October 12, 2021
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphomaAlex F Herrera, Joycelynne Palmer, Vikram Adhikarla, et al.
American Journal of Hematology|March 7, 2023
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusionsIbrahim Aldoss, Michelle Afkhami, Dongyun Yang, et al.
Frontiers in Immunology|March 7, 2025
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxisDiana T Samuels, Janny M Yao, Yazeed Samara, et al.
Transplantation and Cellular Therapy|March 30, 2026
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell TransplantationJorge M Ramos Perez, Haoyue Shan, Dongyun Yang, et al.
Pageof 5